UK Third National Colorectal Cancer Consensus Meeting 2008

Clinical Oncology

Volumn 21, Issue 4, 2009, Pages 306-310

  Glynne Jones, R ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; COLORECTAL CANCER; CONSENSUS; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; MEDICAL FEE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECTUM CANCER; RECTUM SURGERY;

COLORECTAL NEOPLASMS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; GREAT BRITAIN; HUMANS; PREOPERATIVE CARE;

EID: 62749155686     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.01.004     Document Type: Editorial

References (21)

1. Symonds P., and National Colorectal Consensus Group. UK National Colorectal Cancer Consensus Meeting 2006. Clin Oncol (R Coll Radiol) 19 (2007) 234-236
2. Glynne-Jones R. UK second National Colorectal Cancer Consensus Meeting 2007. Clin Oncol (R Coll Radiol) 20 (2008) 365-368
3. Clarke R., Waddell T., Gallagher J., et al. A postcode lottery still exists for cancer patients with exceptional circumstances (Letter). Clin Oncol (R Coll Radiol) 20 (2008) 771-772
4. Sikora K., and James N. Top-up payments in cancer care. Clin Oncol (R Coll Radiol) 21 1 (2009) 1-5
5. Glynne-Jones R., and Beaumont I. Why co-payment is a cop-out for us all. Clin Oncol (R Coll Radiol) 21 1 (2009) 6-7
6. Department of Health. A code of conduct for private practice: recommended standards of practice for NHS consultants (2004), Department of Health, London
7. National Health Service Act 2006. Available from:. http://www.opsi.gov.uk/Acts/acts2006/ukpga_20060041_en_1 [accessed November 2008]
8. Ohlsen A.H., Parkin D.M., and Sasieni P. Cancer mortality in the United Kingdom: projections to the year 2025. Br J Cancer 99 (2008) 1549-1554
9. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336 (1997) 980-987
10. Peeters K.C., Marijnen C.A., Nagtegaal I.D., et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246 (2007) 693-701
11. Sebag-Montefiore D., Steele R., Quirke P., et al. Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. J Clin Oncol 24 Suppl (2006) 3511
12. Pollack J., Holm T., Cedermark B., et al. Late adverse effects of short-course preoperative radiotherapy in rectal cancer. Br J Surg 93 (2006) 1519-1525
13. Birgisson H., Påhlman L., Gunnarsson U., and Glimelius B. Adverse effects of preoperative radiotherapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 34 (2005) 8697-8705
14. Birgisson H., Påhlman L., Gunnarsson U., et al. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23 (2005) 6126-6131
15. Braun M.S., Richman S.D., Adlard J.W., et al. for the FOCUS Trial Investigators. Association of topoisomerase-1 (Topo1) with the efficacy of chemotherapy in a randomized trial for advanced colorectal cancer patients (FOCUS). J Clin Oncol 24 Suppl (2006) 10009
16. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008) 1757-1765
17. Hoskins J.M., Goldberg R.M., Qu P., Ibrahim J.G., and McLeod H.L. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99 (2007) 1290-1295
18. Thomas H.R., Ezzeldin H.H., Guarcello V., Mattison L.K., Fridley B.L., and Diasio R.B. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genom 17 (2007) 973-987
19. Camptosar (irinotecan hydrochloride injection) prescribing information. Available from:. https://www.pfizerpro.com/product_info/camptosar_pi_adverse_reactions.jsp [accessed November 2008]
20. Ando Y., Saka H., Ando M., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60 (2000) 6921-6926
21. Richards M. Improving access to medicines for NHS patients: a report for the Secretary of State for Health by Professor Mike Richards. Available from:. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089927 [accessed November 2008]